Recruitment of Osteoclast Precursors by Stromal Cell Derived Factor-1 (SDF-1) in Giant Cell Tumor of Bone
Overview
Authors
Affiliations
Giant cell tumor (GCT) of bone is a unique bone lesion that is characterized by an excessive number of multinucleated osteoclasts. GCT consists of neoplastic stromal cells, multinucleated osteoclasts and their precursors, thus serving as a naturally occurring human disease model for the study of osteoclastogenesis. It still remains unclear how stromal cells of GCT recruit osteoclast precursors. In the present study, we characterized the cellular components of GCT and confirmed the presence of CD14(+)-monocytes/CD68(+)-macrophages and CD34(+)-hematopoetic stem cells that express CXCR4, a specific receptor for SDF-1; SDF-1 gene expression and presence of SDF-1 protein were confirmed by real time RT-PCR, in situ hybridization, and immunohistochemistry in the GCT tissue and cultured cells. SDF-1 was present at 25-50 ng/ml in the conditioned media from the GCT cultures, which is in the range of physiological chemotactic concentration. Migration of osteoclast precursors was 2.5-fold higher in response to GCT conditioned media compared to the control media; and migration was inhibited by an average of 36% with anti-SDF-1 neutralizing antibody or competing recombinant SDF-1. These results suggest that SDF-1 is one of the significant chemoattractant factors involved in the recruitment of hematopoietic osteoclast precursor cells during tumor-induced osteoclastogenesis.
Exploring the Interplay Between Senescent Osteocytes and Bone Remodeling in Young Rodents.
Song I, Kim P, Choi Y, Chung Y, Lee S, Baek J J Aging Res. 2024; 2024:4213141.
PMID: 39583064 PMC: 11585373. DOI: 10.1155/2024/4213141.
Giant cell tumor of bone and secondary osteoarthritis.
Todi N, Hiltzik D, Moore D Heliyon. 2024; 10(10):e30890.
PMID: 38807896 PMC: 11130671. DOI: 10.1016/j.heliyon.2024.e30890.
Current therapies and future prospective for locally aggressive mesenchymal tumors.
Maleddu A, Zhu J, Clay M, Wilky B Front Oncol. 2023; 13:1160239.
PMID: 37546427 PMC: 10401592. DOI: 10.3389/fonc.2023.1160239.
Venneker S, van Eenige R, Kruisselbrink A, Palubeckaite I, Taliento A, Briaire-de Bruijn I Cancers (Basel). 2022; 14(19).
PMID: 36230631 PMC: 9563449. DOI: 10.3390/cancers14194708.
Tsukamoto S, Mavrogenis A, Hindiskere S, Honoki K, Kido A, Fujii H Curr Oncol. 2022; 29(9):6383-6399.
PMID: 36135072 PMC: 9498107. DOI: 10.3390/curroncol29090503.